RMDN3

Across TCGA pan-cancer cohorts, RMDN3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RMDN3 data layer compared with 21 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RMDN3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RMDN3 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

HNSC, GBM, and CCRCC are the cancer types where RMDN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.548	0.793	.017	14	view →
GBM	DFS	Quartile	All	0.882	0.612	.011	9	view →
CCRCC	DFS	Quartile	III,IV	0.493	0.880	.006	8	view →
LUAD	DFS	Tertile	All	0.593	0.811	.013	5	view →
UCEC	OS	Tertile	All	1.000	0.904	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RMDN3–HNSC (DFS)

Open the HNSC breakdown →